ProCE Banner Activity

CE / CME

Integrating the Latest Treatments for T2D Into Patient Care: Connecting Mechanism of Action to Patient Cases

Video

Experts discuss the use of SGLT2 inhibitors, GLP-1 receptor agonists, and GIP/GLP-1 coagonists in patients with type 2 diabetes and obesity including a focus on complex patients with advanced comorbidities.

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 05, 2023

Expiration: December 04, 2024

No longer available for credit.

Share

Faculty

Vivian A. Fonseca

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Jennifer B Green

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Carol Hatch Wysham

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Provided by

Provided by Clinical Care Options, LLC in partnership with the Endocrine Society

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Endocrine Society

ProCE Banner

Target Audience

This program is intended for US endocrinologists

Program Learning Goal

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with Diabetes

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the latest efficacy and safety data for guideline-recommended treatments for patients who qualify for weight-focused management of T2D

  • Incorporate evidence-based treatments for patients with T2D, obesity, and related comorbidities into clinical decision-making

  • Compare the mechanisms of action of newer treatment options for T2D and their effects on glycemic and metabolic parameters

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences center
New Orleans, Louisiana

Vivian Fonseca, MD, FRCP: researcher (paid to institution): Fractyl, Jaguar Gene Therapy; consultant/advisor/speaker: Abbott, Asahi, Bayer, Boehringer Ingelheim, Corcept; stock/stock options: Abbott, Amgen, BRAVO4Health, Mellitus.

Jennifer B Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Jennifer Green, MD: consultant/advisor/speaker: Anji, AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, Merck, Novo Nordisk, Pfizer, Valo, Vertex; researcher: Boehringer Ingelheim, Merck, Roche.

Carol Hatch Wysham, MD

Clinical Professor of Medicine
Clinical Endocrinologist
MultiCare/Rockwood Clinic
Spokane, Washington

Carol Hatch Wysham, MD: consultant/advisor/speaker: Abbott, Biomea. researcher: Corcept, Bayer, Eli Lilly, Novo Nordisk, Regeneron, Vanda.

The planners and content peer reviewers from Clinical Care Options, LLC and the Endocrine Society do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from December 05, 2023, through December 04, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME for MIPS

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

In order to fulfill requirements for MIPS improvement activity, participants will need to fill out 2 brief follow-up surveys at 30- and 90-days post-activity.